# Bharat Biotech Returns to Innovation After Pandemic

> Bharat Biotech founder Krishna Ella reveals post-Covid reset, TB vaccine progress, and future focus on Africa.
- Title: Bharat Biotech Returns to Innovation After Pandemic | Shortify
- Summary: Bharat Biotech founder Krishna Ella reveals post-Covid reset, TB vaccine progress, and future focus on Africa. Bharat Biotech aims to make gene therapy…
- Keywords: bharat biotech, krishna ella, tb vaccine, nipah vaccine, ebola vaccine, gene therapy, monoclonal antibodies, ipo, india, africa, covaxin, Bharat
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/bharat-biotech-is-back-in-action-after-covid-reset-krishna-ella-on-tb-vaccine-nipah-ebola-shots-gene-therapy-ipo-plans-whats-next/articleshow/134397339.cms
- Author: Rica Bhattacharyya
- Published: 2026-09-21T19:43:00+00:00
- Read time: 1 min
- Topics: bharat biotech, krishna ella, tb vaccine, nipah vaccine, ebola vaccine, gene therapy, monoclonal antibodies, ipo, india, africa, covaxin
## Post-Covid Reset
Bharat Biotech founder Krishna Ella says the company took two years to reset after pandemic work.

> Momentum fizzled out a little bit. Employees also lost energy after working so hard in the Covid time.
## TB Vaccine Progress
The TB vaccine has completed phase 2 trials and is submitting phase 3 data for review.

> Phase 2 is completed. Submitting the dossier; it has been reviewed already.
## Gene Therapy Focus
Bharat Biotech aims to make gene therapy affordable for India's middle class through Bengaluru facility.

> Today the therapy costs Rs 1-3 crore or even more. Our aim is to make it affordable.
## Nipah and Ebola Vaccines
Krishna Ella is developing Nipah and Ebola vaccines with a focus on T-cell-based approaches for pandemic preparedness.

> I am now focusing on two pandemic vaccines from the point of view of preparedness. One is a Nipah vaccine and the second is Ebola.
## IPO Plans
Bharat Biotech is exploring IPO options to fund new therapies and de-risk investments.

> I am not denying it. But definitely when I want to go to new therapies like monoclonal antibodies, I need some money to push the game.
## Next Generation
Krishna Ella's children are leading human vaccines and gene therapy efforts, with daughter focusing on veterinary science.

> My son (Raches Ella) is looking after the human vaccines and gene therapy. My daughter (Jalachari Ella) is on the veterinary side.
## Africa Focus
Bharat Biotech aims to become a major public health contributor for Africa through vaccines and veterinary programs.

> I want to help the African continent with human vaccines, veterinary, and agriculture.
## Financial Strategy
Bharat Biotech has Rs 2,000 crore revenue, is debt-free, and invested Rs 1,500 crore in Odisha manufacturing.

> We are around Rs 2,000 crore revenue now. But we are stabilised. We are a debt-free company.
## Key takeaway

Bharat Biotech aims to make gene therapy affordable for India's middle class and target African health needs.